Showing 7811-7820 of 9757 results for "".
- IMMpactful: Risankizumab Outperforms Deucravacitinib in Moderate Psoriasis at 16 Weekshttps://practicaldermatology.com/news/immpactful-risankizumab-outperforms-deucravacitinib-in-moderate-psoriasis-at-16-weeks/2486443/Risankizumab achieved higher rates of PASI 90 and PASI 100 compared with deucravacitinib at 16 weeks, alongside greater improvements in patient-reported symptoms and quality of life, new results from the IMMpactful trial suggested.
- Povorcitinib Shows Durable Efficacy in HS in Phase 3 STOP-HS Trialshttps://practicaldermatology.com/news/povorcitinib-shows-durable-efficacy-in-hs-in-phase-3-stop-hs-trials/2486420/Late-breaking results from the Phase 3 STOP-HS1 and STOP-HS2 trials presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting showed that povorcitinib, an oral JAK1-selective inhibitor, achieved sustained efficacy and a manageable safety profile through 54 weeks in patients with
- Bimekizumab Shows Durable Psoriasis Clearance and 3-Year HS Controlhttps://practicaldermatology.com/news/bimekizumab-shows-durable-psoriasis-clearance-and-3-year-hs-control/2486394/New analyses from the BE RADIANT and BE VIVID trials showed the durability of response with bimekizumab (Bimzelx; UCB) in treating plaque psoriasis, alongside positive long-term findings in hidradenitis suppurativa (HS). Resu
- Most Nations Off Track to Meet 2030 Skin NTD SDG Targets: Reporthttps://practicaldermatology.com/news/most-nations-off-track-to-meet-2030-skin-ntd-sdg-targets-report/2485823/A new report in JAMA Dermatology revealed that most countries are unlikely to achieve the World Health Organization (WHO) target of a 75% reduction in disability-adjusted life-years (DALYs) from skin-related neglected tropical diseases (NTDs) from 2020 lev
- South Beach Symposium: Dr. Neal Neal Bhatia Maps a Fragmented but Promising Pipelinehttps://practicaldermatology.com/news/south-beach-symposium-dr-neal-neal-bhatia-maps-a-fragmented-but-promising-pipeline/2485624/At the 2026 South Beach Symposium, Neal Bhatia, MD, FAAD, delivered a wide-ranging and opinionated overview of the current dermatology therapeutic landscape, arguing that Innovation is uneven across disease states and increasi
- Danish Registry Study Shows Rising cSCC and CIS Incidence Over 18 Yearshttps://practicaldermatology.com/news/nearly-two-decades-of-data-highlight-shifting-patterns-in-keratinocyte-neoplasms/2485635/Incidence rates of cutaneous squamous cell carcinoma (cSCC) and cSCC in situ (CIS) have continued to rise in Denmark over nearly two decades, while keratoacanthoma (KA) incidence has declined, according to a large population-based registry study.
- Icotrokinra Maintains Psoriasis Responses With Continuous Treatmenthttps://practicaldermatology.com/news/icotrokinra-maintains-psoriasis-responses-with-continuous-treatment/2485554/Continuous treatment with icotrokinra resulted in durable psoriasis control through one year, while treatment withdrawal was associated with rapid loss of response, according to “Maintenance of Response With Icotrokinra for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results From the Ph
- ORKA-001 Phase 1 Data Support Potential Once-Yearly IL-23 Dosinghttps://practicaldermatology.com/news/orka-001-phase-1-data-support-potential-once-yearly-il-23-dosing/2485550/A half-life–extended IL-23p19 monoclonal antibody demonstrated sustained pharmacokinetics and favorable tolerability that may support once-yearly dosing in plaque psoriasis, according to “Phase 1 Clinical Data of ORKA-001, a Novel Half-Life–Extended IL-23p19 Monoclonal Antibody,” a poster by Jame
- Intralesional Cemiplimab Shows High Pathologic Response in Early-Stage CSCChttps://practicaldermatology.com/news/intralesional-cemiplimab-shows-high-pathologic-response-in-early-stage-cscc/2485540/Low-dose intralesional cemiplimab produced high objective and pathologic response rates without treatment-limiting toxicity in patients with early-stage cutaneous squamous cell carcinoma (CSCC), according to “Intralesional Cemiplimab for Patients With Early-Stage Cutaneous Squamous Cell Carcinoma
- Rapid Regrowth Tops Treatment Goals for Alopecia Areata: Surveyhttps://practicaldermatology.com/news/rapid-regrowth-tops-treatment-goals-for-alopecia-areata-survey-finds/2485419/Results from a new national survey presented at the 2026 Winter Clinical Dermatology Hawaii reveals that most US clinicians prioritize rapid and nearly complete hair regrowth, with strong satisfaction reported for Janus kinase (JAK) inhibitor therapies.